Educational protocol hub
AOD-9604: protocol variants and reconstitution resources
Educational hub for AOD-9604, grouping 3 available protocol variants with links to the exact dosage and reconstitution pages.
What this hub covers
This page groups the available AOD-9604 protocol variants so readers can choose the exact vial-size guide without mixing formats.
Reconstitution workflow
Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.
Research-only context
All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.
Available protocol variants
Choose the exact guide you want to view.
AOD-9604
AOD-9604 dosing protocols utilize this synthetic 16-amino acid fragment (Tyr‑hGH 177–191) to support lipolysis and inhibit lipogenesis without increasing IGF‑1 or causing insulin resistance. Clinical trials showed a safety profile similar to placebo in obese adults. This protocol outlines a once-daily subcutaneous approach with the 2 mg vial.
View protocolAOD-9604
AOD-9604 dosing protocols leverage this synthetic 16-amino acid fragment (Tyr‑hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without increasing IGF‑1 levels or inducing insulin resistance. Clinical trials have shown AOD‑9604 exhibits a safety profile similar to placebo in obese adults. This educational protocol outlines a once-daily subcutaneous approach with a practical dilution for accurate insulin syringe measurements.
View protocolAOD-9604
AOD-9604 is a modified fragment (Frag 176-191) of human growth hormone studied for lipolysis without the anabolic effects of HGH. 10 mg vial.
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
References
- Journal of Endocrinology and Metabolism (2014) — Safety and metabolism of AOD9604
View Source - Journal of Endocrinology and Metabolism (2013) — Safety and tolerability of AOD9604 in humans
View Source - FDA PCAC (2024) — Memorandum on AOD‑9604 bulk drug substance
View Source - Endocrinology (OUP) — Effects of hGH and AOD9604 on lipid metabolism
View Source - Gastroenterology — AOD‑9604 clinical results in an RCT
View Source - Bachem Peptide Guide — Peptide handling and storage guidelines
View Source - Wilding J Curr Opin Investig Drugs 2004 — AOD-9604 Metabolic.
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.